Previous close | 389.70 |
Open | 390.60 |
Bid | 391.40 x N/A |
Ask | 391.60 x N/A |
Day's range | 389.90 - 393.00 |
52-week range | 308.37 - 393.00 |
Volume | |
Avg. volume | 18,289,867 |
Market cap | 35.81B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 32.75 |
EPS (TTM) | 0.12 |
Earnings date | 01 Aug 2024 |
Forward dividend & yield | 0.06 (1.59%) |
Ex-dividend date | 15 Aug 2024 |
1y target est | 367.56 |
Eroxon®, the first-and-only FDA cleared gel available without a prescription for the treatment of erectile dysfunction (ED), is now available for pre-order in the United States through Amazon and will be available at most major retailers in October 2024.
Haleon’s latest half-year results were highly encouraging, but not necessarily for the reasons that investors assume.
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Short Sellers. In this article, we are going to take a look at where Haleon plc (NYSE:HLN) stands against the other cheap pharmaceutical stocks. The pharmaceutical industry is one of the most interesting sectors to invest in. This is because while […]